NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V.
Your view on NAMSW
Overview
What the company does, where it operates, and who runs it.
About NewAmsterdam Pharma Company N.V.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Michael Harvey Davidson Facp.
- Headquarters
- Gooimeer 2-35, Naarden, NH, NL
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Michael Harvey Davidson Facp.
- Headquarters
- Gooimeer 2-35, Naarden, NH, NL
NewAmsterdam Pharma Company N.V. is a biopharmaceutical firm currently in the clinical development phase, committed to enhancing therapeutic options for individuals living with metabolic diseases.
The company's primary experimental treatment, obicetrapib, is an innovative, selective agent designed to inhibit Cholesteryl Ester Transfer Protein (CETP).
Clinical trials have shown this compound to be effective in both lowering "bad" low-density lipoprotein cholesterol (LDL-C) and significantly elevating "good" high-density lipoprotein cholesterol (HDL-C) simultaneously. Founded in 2019, this Dutch company maintains its headquarters in Naarden.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for NewAmsterdam Pharma Company N.V. from FRC's valuation model, read against the market price. NAMSW last traded at $9.31; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for NewAmsterdam Pharma Company N.V.. Starting points for NewAmsterdam Pharma Company N.V.: EPS -$1.65, beta 0.11 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for NewAmsterdam Pharma Company N.V.. NewAmsterdam Pharma Company N.V. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for NewAmsterdam Pharma Company N.V.. Trailing twelve-month EPS for NewAmsterdam Pharma Company N.V. stands at -$1.65. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.45 | -$0.53 | -$1.54 | -$1.94 |
| Low estimate | -$0.45 | -$0.53 | -$5.94 | -$7.49 |
| High estimate | -$0.45 | -$0.53 | $0.00 | $0.00 |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago EPS | -$0.65 | -$0.40 | -$1.75 | — |
| Growth | +30.4% | -32.8% | +11.9% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $13.98M | $1.41M | $40.04M | $67.46M |
| Low estimate | $13.98M | $1.41M | $21.91M | $247154.00 |
| High estimate | $13.98M | $1.41M | $67.53M | $288.41M |
| No. of analysts | 15 | 6 | 14 | 15 |
| Year-ago revenue | $32000.00 | $3.04M | $22.50M | — |
| Growth | +43602.4% | -53.5% | +77.9% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for NewAmsterdam Pharma Company N.V.. NewAmsterdam Pharma Company N.V. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
NewAmsterdam Pharma Company N.V. valued side by side against its closest peers. NewAmsterdam Pharma Company N.V. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by NewAmsterdam Pharma Company N.V. executives and directors. Shares of NewAmsterdam Pharma Company N.V. have traded between $12.25 and $30.45 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for NewAmsterdam Pharma Company N.V.. Coverage tracks NewAmsterdam Pharma Company N.V. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of NewAmsterdam Pharma Company N.V.